Diabetes Mellitus Type 2NCT07793292
Telehealth Educational Intervention for Adults With Type 2 Diabetes in Oman
A study testing Telehealth Educational Intervention in people with Diabetes Mellitus Type 2, run by Sultan Qaboos University at 1 site in Oman.
Trial summary
The goal of this clinical trial is to find out whether adding a nurse-led telehealth educational program to usual diabetes care can improve blood sugar control, medication-related behaviors, and quality of life in adults with type 2 diabetes in Oman. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus Type 2
- What is being tested?
- Telehealth Educational Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteOman
- Study dates
- 1 Nov 2026to 30 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet all of the following:
- Omani national aged 18 years or older.
- Confirmed type 2 diabetes mellitus (T2DM) documented in the medical record.
- Prescribed at least one glucose-lowering medication and receiving treatment for at least 3 months before enrollment.
- Most recent clinically valid HbA1c, or screening HbA1c when appropriate, 7.5% or higher.
- Access to an internet-enabled smartphone, tablet, or computer and ability to participate in video- or audio-supported telehealth sessions.
- Able to understand Arabic or English sufficiently to provide informed consent and participate in study procedures, and able to complete the validated Arabic Oman version of the medication-adherence questionnaire.
- Willingness to be randomized and availability for 6 months of follow-up.
Who cannot join
- Type 1 diabetes, gestational diabetes, or another diabetes type for which the intervention and outcome plan is not appropriate.
- Current pregnancy or planned pregnancy during follow-up.
- Severe cognitive impairment, active psychosis, or another condition preventing informed consent or meaningful participation.
- Acute medical instability or hospital admission at recruitment.
- Participation in another interventional study that could materially affect trial outcomes.
- Inability to use telehealth even with reasonable assistance or absence of a private and safe setting for sessions.
- Another clinical or ethical reason identified by the treating clinician or principal investigator that makes participation inappropriate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Oman1 site
Sultan Qaboos University Hospital
Muscat, Al Khoud, 123
Nahla Al Aali, PhD, +96899486539, n.alaali@squ.edu.om
n.alaali@squ.edu.om
About this study
Official title: Effectiveness of a Telehealth Educational Intervention on Glycemic Control, Medication Adherence, and Quality of Life Among Adults With Type 2 Diabetes in Oman: Study Protocol for a Two-Arm Parallel Randomized Controlled Trial
The goal of this clinical trial is to find out whether adding a nurse-led telehealth educational program to usual diabetes care can improve blood sugar control, medication-related behaviors, and quality of life in adults with type 2 diabetes in Oman.
The main question this study aims to answer is whether adults who receive the telehealth educational program, in addition to their usual diabetes care, have better blood sugar control after 6 months than adults who receive usual diabetes care alone. Blood sugar control will be assessed using hemoglobin A1c (HbA1c), a blood test that reflects average blood sugar levels over the previous few months.
Read more
The study will also examine whether the telehealth program improves participants' attitudes and behaviors related to taking their diabetes medicines and their diabetes-related quality of life. Among participants receiving the telehealth intervention, the study will also assess how easy, useful, reliable, and satisfactory they find the telehealth service.
Approximately 160 Omani adults with type 2 diabetes will take part in the study. Participants will be randomly assigned to one of two groups. One group will continue usual diabetes care and will also receive an individual telehealth education session once a week for 24 weeks. Each session will last about 20 to 30 minutes and will be provided by a trained nurse using an approved secure telehealth platform. The sessions will cover topics such as diabetes and HbA1c, safe use of medicines, strategies for remembering medicines, healthy eating, physical activity, blood glucose monitoring, recognition of low and high blood sugar, prevention of diabetes complications, stress and sleep, and communication with healthcare professionals.
The other group will continue to receive usual diabetes care without the additional study telehealth education program. No established diabetes care will be withheld from either group, and the telehealth education will not replace routine medical care or authorize the research team to change participants' medications.
Participants will be assessed at the start of the study, at 3 months, and at 6 months. Assessments will include HbA1c testing and questionnaires about medication-related beliefs and behaviors and diabetes-related quality of life. Participants in the telehealth group will also complete a questionnaire about their experience with and satisfaction with telehealth.
Read the detailed description
Type 2 diabetes requires ongoing self-management between routine clinic visits. This includes taking medications as prescribed, following healthy eating and physical activity recommendations, monitoring blood glucose when appropriate, and recognizing and preventing complications. Regular clinic visits may not provide enough time for repeated education, reinforcement, and problem-solving. Telehealth may provide a practical way to extend structured diabetes education beyond face-to-face visits and offer more continuous support. However, randomized evidence on culturally tailored, nurse-led telehealth education for adults with type 2 diabetes in Oman remains limited.
This study is a prospective, single-site, two-arm, parallel-group randomized controlled trial designed to evaluate the effectiveness of a structured telehealth educational intervention for adults with type 2 diabetes in Oman. The study will compare usual diabetes care plus telehealth education with usual diabetes care alone. The main aim is to determine whether adding telehealth education to usual care improves glycemic control over 6 months. The study will also examine medication-related beliefs and behaviors, diabetes-related quality of life, and participants' experiences with telehealth.
The telehealth intervention will be delivered individually by a trained diabetes nurse educator or research nurse using an institutionally approved secure platform. Participants assigned to the intervention group will receive one telehealth education session each week for 24 weeks, in addition to their usual diabetes care. Sessions will generally last 20 to 30 minutes and will be provided in Arabic or English according to participant preference and need.
During the first 12 weeks, participants will receive a structured educational curriculum. Topics will include understanding type 2 diabetes and hemoglobin A1c (HbA1c), safe use of diabetes medicines, strategies for remembering medicines, healthy eating, physical activity, blood glucose monitoring, recognition and management of low and high blood sugar, and prevention of diabetes-related complications. Education will also address managing diabetes during illness, travel, fasting, and changes in daily routines; stress and sleep; social support; communication with healthcare professionals; and long-term self-management planning. During weeks 13 to 24, the sessions will reinforce earlier content, review personal goals, address barriers, and revisit topics according to participants' needs.
The intervention is educational and will not replace routine clinical care. Research staff will not start, stop, or change participants' medications. Questions requiring clinical decisions will be referred to the participant's treating healthcare team. Participants in the comparison group will continue to receive the usual diabetes care provided by Sultan Qaboos University Hospital, including routine clinical follow-up, medication management, laboratory testing, and standard diabetes education.
The primary focus of the trial is glycemic control, assessed using HbA1c. The study will also evaluate medication-related beliefs and behaviors and diabetes-specific quality of life. Among participants receiving telehealth education, the study will assess perceptions of the usefulness, ease of use, reliability, and satisfaction with telehealth. Information on participation in telehealth sessions, technical problems, intervention delivery, retention, referrals, and safety will also be collected to help determine the feasibility and acceptability of the program.
The first 30 randomized participants will form an internal feasibility pilot. This pilot will examine recruitment, consent, attendance, platform performance, data completeness, privacy issues, and participant retention. It will not include formal comparative testing of the effectiveness of the intervention. Findings from the pilot may be used to make minor operational improvements that do not change the study objectives, eligibility criteria, outcomes, or randomization procedures.
This study is expected to provide evidence about whether a structured, culturally tailored, nurse-led telehealth education program can strengthen diabetes self-management and improve outcomes for adults with type 2 diabetes in Oman. If the program is effective and acceptable, it may provide a model for extending diabetes education and support beyond routine clinic visits.
- Conditions
- Diabetes Mellitus Type 2
- Being tested
- Telehealth Educational Intervention
- Keywords
- Telemedicine; Patient Education; Medication Adherence; Glycated Hemoglobin; Quality of Life; Oman
- Medical subject headings
- Diabetes Mellitus, Type 2, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Telehealth Educational InterventionBehavioural
Participants assigned to the intervention group will receive usual diabetes care plus one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an SQU/SQUH-approved secure platform. Video will be encouraged when feasible; secure audio may be used if connectivity is insufficient. The first 12 weeks will follow a standardized curriculum covering diabetes and HbA1c, medication use and adherence strategies, healthy eating, physical activity, glucose monitoring, hypo- and hyperglycemia, complication prevention, stress and sleep, communication with healthcare professionals, and maintenance planning. Weeks 13-24 will reinforce content, review goals, address barriers, and revisit topics as needed. Research staff will not initiate, discontinue, or adjust medications; clinical questions will be referred to the treating team.
| Study group | Role | What they receive |
|---|---|---|
| Usual Care Plus Telehealth Education | Experimental | Participants will continue usual diabetes care and receive one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an institutionally approved secure platform. The first 12 weeks will follow a standardized diabetes education curriculum, and weeks 13-24 will reinforce content, review personal goals, address barriers, and revisit topics as needed. The intervention is educational; research staff will not initiate, discontinue, or adjust medications. Receives: Behavioral: Telehealth Educational Intervention |
| Usual Care Alone | Active comparator | This group continues established usual diabetes care at SQUH, including routine clinic review, medication management, laboratory testing, and standard education. Receives: Behavioral: Telehealth Educational Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months
Measure: Change in Hemoglobin A1c (HbA1c) Description: HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
Measured: Baseline to 6 months
Change in Hemoglobin A1c (HbA1c)
HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
Measured: Baseline to month 6.
Secondary outcomes (4)
Change in Positive Attitudes Towards Healthcare and Medication Score From Baseline to 6 Months
Measured using the Positive Attitudes Towards Healthcare and Medication domain of the MAUQ-ar-OM. The month-6 comparison is the principal secondary comparison; month 3 is supportive.
Measured: Baseline to 6 Months
Change in Diabetes-Specific Quality of Life From Baseline to 6 Months
Measured using the Diabetes Quality of Life Brief Clinical Inventory (DQOL-15). The month-6 comparison is principal; month 3 is supportive.
Measured: From Baseline to 6 Months
Change in Medication-Adherence Beliefs and Behaviors
Includes the MAUQ-ar-OM domains for lack of discipline, aversion towards medication, active coping with health problems, and the overall MAUQ-ar-OM score. Assessed at baseline, 3 months, and 6 months.
Measured: Assessed at baseline, 3 months, and 6 months.
Telehealth Usability and Satisfaction
Measured with the Arabic Telehealth Usability Questionnaire (TUQ-Arabic) at months 3 and 6, intervention group only. Your protocol treats this as a secondary outcome rather than a randomized between-group comparison.
Measured: at months 3 and 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2026
- Study start1 Nov 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, single-site, two-arm, parallel-group superiority randomized controlled trial with 1:1 allocation. After informed consent and baseline assessment, participants will be randomly assigned to usual diabetes care plus weekly telehealth education for 24 weeks or to usual diabetes care alone. Outcomes will be assessed at baseline, 3 months, and 6 months. Randomization will use concealed, randomly varied block sizes of 4 and 6, stratified by sex and baseline HbA1c (\<9.0% vs ≥9.0%).
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sultan Qaboos University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Nahla Al Ali, Sultan Qaboos University
- Investigators
- Nahla Mansour Al Aali, PhD, Principal investigator, College of Nursing, Sultan Qaboos University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07793292
- Sponsor's protocol ID
- IG/--/CON/C&M/26/389
- Status last verified
- Aug 2026
- First submitted
- 25 Aug 2026
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data and analysis code may be shared after publication of the primary study findings upon reasonable request. Access will be subject to approval by the principal investigator, relevant institutional and ethics authorities, and completion of an appropriate data-use agreement.
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of a Telehealth Educational Intervention on Glycemic Control, Medication Adherence, and Quality of Life Among Adults With Type 2 Diabetes in Oman: Study Protocol for a Two-Arm Parallel Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07793292
- Acronym / sponsor ID
- IG/--/CON/C&M/26/389
- Conditions
- Diabetes Mellitus Type 2
- Keywords
- Telemedicine; Patient Education; Medication Adherence; Glycated Hemoglobin; Quality of Life; Oman
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Sultan Qaboos UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Jan 2028 (estimated)
- First posted
- 28 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find out whether adding a nurse-led telehealth educational program to usual diabetes care can improve blood sugar control, medication-related behaviors, and quality of life in adults with type 2 diabetes in Oman.
The main question this study aims to answer is whether adults who receive the telehealth educational program, in addition to their usual diabetes care, have better blood sugar control after 6 months than adults who receive usual diabetes care alone. Blood sugar control will be assessed using hemoglobin A1c (HbA1c), a blood test that reflects average blood sugar levels over the previous few months.
The study will also examine whether the telehealth program improves participants' attitudes and behaviors related to taking their diabetes medicines and their diabetes-related quality of life. Among participants receiving the telehealth intervention, the study will also assess how easy, useful, reliable, and satisfactory they find the telehealth service.
Approximately 160 Omani adults with type 2 diabetes will take part in the study. Participants will be randomly assigned to one of two groups. One group will continue usual diabetes care and will also receive an individual telehealth education session once a week for 24 weeks. Each session will last about 20 to 30 minutes and will be provided by a trained nurse using an approved secure telehealth platform. The sessions will cover topics such as diabetes and HbA1c, safe use of medicines, strategies for remembering medicines, healthy eating, physical activity, blood glucose monitoring, recognition of low and high blood sugar, prevention of diabetes complications, stress and sleep, and communication with healthcare professionals.
The other group will continue to receive usual diabetes care without the additional study telehealth education program. No established diabetes care will be withheld from either group, and the telehealth education will not replace routine medical care or authorize the research team to change participants' medications.
Participants will be assessed at the start of the study, at 3 months, and at 6 months. Assessments will include HbA1c testing and questionnaires about medication-related beliefs and behaviors and diabetes-related quality of life. Participants in the telehealth group will also complete a questionnaire about their experience with and satisfaction with telehealth.
Detailed description
Type 2 diabetes requires ongoing self-management between routine clinic visits. This includes taking medications as prescribed, following healthy eating and physical activity recommendations, monitoring blood glucose when appropriate, and recognizing and preventing complications. Regular clinic visits may not provide enough time for repeated education, reinforcement, and problem-solving. Telehealth may provide a practical way to extend structured diabetes education beyond face-to-face visits and offer more continuous support. However, randomized evidence on culturally tailored, nurse-led telehealth education for adults with type 2 diabetes in Oman remains limited.
This study is a prospective, single-site, two-arm, parallel-group randomized controlled trial designed to evaluate the effectiveness of a structured telehealth educational intervention for adults with type 2 diabetes in Oman. The study will compare usual diabetes care plus telehealth education with usual diabetes care alone. The main aim is to determine whether adding telehealth education to usual care improves glycemic control over 6 months. The study will also examine medication-related beliefs and behaviors, diabetes-related quality of life, and participants' experiences with telehealth.
The telehealth intervention will be delivered individually by a trained diabetes nurse educator or research nurse using an institutionally approved secure platform. Participants assigned to the intervention group will receive one telehealth education session each week for 24 weeks, in addition to their usual diabetes care. Sessions will generally last 20 to 30 minutes and will be provided in Arabic or English according to participant preference and need.
During the first 12 weeks, participants will receive a structured educational curriculum. Topics will include understanding type 2 diabetes and hemoglobin A1c (HbA1c), safe use of diabetes medicines, strategies for remembering medicines, healthy eating, physical activity, blood glucose monitoring, recognition and management of low and high blood sugar, and prevention of diabetes-related complications. Education will also address managing diabetes during illness, travel, fasting, and changes in daily routines; stress and sleep; social support; communication with healthcare professionals; and long-term self-management planning. During weeks 13 to 24, the sessions will reinforce earlier content, review personal goals, address barriers, and revisit topics according to participants' needs.
The intervention is educational and will not replace routine clinical care. Research staff will not start, stop, or change participants' medications. Questions requiring clinical decisions will be referred to the participant's treating healthcare team. Participants in the comparison group will continue to receive the usual diabetes care provided by Sultan Qaboos University Hospital, including routine clinical follow-up, medication management, laboratory testing, and standard diabetes education.
The primary focus of the trial is glycemic control, assessed using HbA1c. The study will also evaluate medication-related beliefs and behaviors and diabetes-specific quality of life. Among participants receiving telehealth education, the study will assess perceptions of the usefulness, ease of use, reliability, and satisfaction with telehealth. Information on participation in telehealth sessions, technical problems, intervention delivery, retention, referrals, and safety will also be collected to help determine the feasibility and acceptability of the program.
The first 30 randomized participants will form an internal feasibility pilot. This pilot will examine recruitment, consent, attendance, platform performance, data completeness, privacy issues, and participant retention. It will not include formal comparative testing of the effectiveness of the intervention. Findings from the pilot may be used to make minor operational improvements that do not change the study objectives, eligibility criteria, outcomes, or randomization procedures.
This study is expected to provide evidence about whether a structured, culturally tailored, nurse-led telehealth education program can strengthen diabetes self-management and improve outcomes for adults with type 2 diabetes in Oman. If the program is effective and acceptable, it may provide a model for extending diabetes education and support beyond routine clinic visits.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, single-site, two-arm, parallel-group superiority randomized controlled trial with 1:1 allocation. After informed consent and baseline assessment, participants will be randomly assigned to usual diabetes care plus weekly telehealth education for 24 weeks or to usual diabetes care alone. Outcomes will be assessed at baseline, 3 months, and 6 months. Randomization will use concealed, randomly varied block sizes of 4 and 6, stratified by sex and baseline HbA1c (<9.0% vs ≥9.0%).
| Arm | Type | Receives |
|---|---|---|
| Usual Care Plus Telehealth Education | Experimental | Behavioral: Telehealth Educational InterventionParticipants will continue usual diabetes care and receive one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an institutionally approved secure platform. The first 12 weeks will follow a standardized diabetes education curriculum, and weeks 13-24 will reinforce content, review personal goals, address barriers, and revisit topics as needed. The intervention is educational; research staff will not initiate, discontinue, or adjust medications. |
| Usual Care Alone | Active comparator | Behavioral: Telehealth Educational InterventionThis group continues established usual diabetes care at SQUH, including routine clinic review, medication management, laboratory testing, and standard education. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Participants must meet all of the following:
- Omani national aged 18 years or older.
- Confirmed type 2 diabetes mellitus (T2DM) documented in the medical record.
- Prescribed at least one glucose-lowering medication and receiving treatment for at least 3 months before enrollment.
- Most recent clinically valid HbA1c, or screening HbA1c when appropriate, 7.5% or higher.
Key exclusion criteria (7 listed)
- Type 1 diabetes, gestational diabetes, or another diabetes type for which the intervention and outcome plan is not appropriate.
- Current pregnancy or planned pregnancy during follow-up.
- Severe cognitive impairment, active psychosis, or another condition preventing informed consent or meaningful participation.
- Acute medical instability or hospital admission at recruitment.
- Participation in another interventional study that could materially affect trial outcomes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Telehealth Educational InterventionParticipants assigned to the intervention group will receive usual diabetes care plus one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an SQU/SQUH-approved secure platform. Video will be encouraged when feasible; secure audio may be used if connectivity is insufficient. The first 12 weeks will follow a standardized curriculum covering diabetes and HbA1c, medication use and adherence strategies, healthy eating, physical activity, glucose monitoring, hypo- and hyperglycemia, complication prevention, stress and sleep, communication with healthcare professionals, and maintenance planning. Weeks 13-24 will reinforce content, review goals, address barriers, and revisit topics as needed. Research staff will not initiate, discontinue, or adjust medications; clinical questions will be referred to the treating team. | Behavioural | Usual Care Alone, Usual Care Plus Telehealth Education |
Primary outcome
Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months
Time frame: Baseline to 6 months
Measure: Change in Hemoglobin A1c (HbA1c) Description: HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
Change in Hemoglobin A1c (HbA1c)
Time frame: Baseline to month 6.
HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
4 secondary outcomes
Change in Positive Attitudes Towards Healthcare and Medication Score From Baseline to 6 Months
Time frame: Baseline to 6 Months
Change in Diabetes-Specific Quality of Life From Baseline to 6 Months
Time frame: From Baseline to 6 Months
Change in Medication-Adherence Beliefs and Behaviors
Time frame: Assessed at baseline, 3 months, and 6 months.
Telehealth Usability and Satisfaction
Time frame: at months 3 and 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data and analysis code may be shared after publication of the primary study findings upon reasonable request. Access will be subject to approval by the principal investigator, relevant institutional and ethics authorities, and completion of an appropriate data-use agreement.
Related trials for Diabetes Mellitus Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nahla Mansour Al Aali, PhD principal investigator
College of Nursing, Sultan Qaboos University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Telehealth Educational Intervention in people with Diabetes Mellitus Type 2, run by Sultan Qaboos University at 1 site in Oman.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Oman. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nahla Mansour Al Aali, PhD (+96899486539, n.alaali@squ.edu.om), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months (time frame: Baseline to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.